Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapiesDenise M. Wolf, Laura van ‘t Veer, Christina Yau et al.|Cancer Cell|2022Cited by 335
Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumorsImke H. Bartelink, Laura van ‘t Veer, Jean-Philippe Coppé et al.|Breast Cancer Research|2017Cited by 24
Abstract P6-11-02: Spatial distribution of veliparib measured by matrix assisted laser desorption ionization mass spectrometry in triple negative breast cancer tumorsImke H. Bartelink, Laura van ‘t Veer, Brendan Prideaux et al.|Cancer Research|2015Cited by 0
Biomarkers for Predicting Response to HER2-targeted TherapiesPei Rong Evelyn Lee|eScholarship (California Digital Library)|2018Cited by 0